Lytix Biopharma

Focus: Lytix Biopharma is a Norwegian public biotech company specializing in oncolytic peptide therapeutics with a primary focus on oncology indications. The company operates at clinical stage with a diversified pipeline spanning Phase 1-2 programs.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

About Lytix Biopharma

AI assessmentNot Hiring

No open roles listed right now. Follow Lytix Biopharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

9 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

LTX-315

Carcinoma

Phase 1

Clinical Trials (1)

NCT01223209A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma

Phase 1

Help build intelligence for Lytix Biopharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Proprietary oncolytic peptide platform offers deep scientific differentiation in an immunotherapy-adjacent space with combination potential (LTX-315 + pembrolizumab in melanoma)
Early-stage pipeline breadth (9 active programs across oncology and dermatology) creates multiple career-developing project cycles and cross-functional collaboration opportunities
Public company status provides equity exposure and potential for rapid value creation during clinical inflection points (Phase 2 catalysts in melanoma, sarcoma)

Watch Out For

Currently zero open job postings signals minimal near-term hiring and potential resource constraints despite public status
Pre-commercial stage with no marketed products means no revenue base, limited salary benchmarking, and execution risk if Phase 2 programs underperform

Generated by Claude from Lytix Biopharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

LTX-315

Cancer With Transdermal Accessible Tumour

Phase 1

Clinical Trials (1)

NCT01058616Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour

Phase 1

LTX-315 consecutive lesions

Cancer

Phase 1

Clinical Trials (1)

NCT01986426LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

Phase 1

LTX-109

Nasal Carriers MRSA

Phase 1/2

Clinical Trials (1)

NCT01158235A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA)

Phase 1/2

LTX-315 + pembrolizumab

Melanoma Stage IIIB-IV

Phase 2

Clinical Trials (1)

NCT06651151NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma

Phase 2

LTX-109 1 %

Non-bullous Impetigo

Phase 2

Clinical Trials (1)

NCT01803035A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo